English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/190553
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Fine-tuning DREAM signaling using chemical tools for neurodegenerative disease treatment

AuthorsGutiérrez-Rodríguez, Marta ; Cercós, Pilar ; Izquierdo García, Carolina; Peraza, Diego A.; López-Hurtado, Alejandro; González Pérez, Paz; Dopazo, Xose M.; Herranz, Rosario ; González, Teresa ; Mellström, Britt; Martín-Martínez, Mercedes ; Naranjo, José Ramón; Valenzuela, Carmen
Issue Date2019
Citation6th ECBS/LS-EuChemS Meeting (2019)
AbstractDREAM (Downstream Regulatory Element Antagonist Modulator), also known as KChIP-3 or calsenilin, is a multifunctional calcium binding protein that controls the expression level and/or the activity of several proteins related to calcium homeostasis, neuronal excitability and neuronal survival. As an auxiliary protein in the plasma membrane, DREAM interacts with, and regulates, the gating of KV4 potassium channels, L- and T-type voltage-dependent calcium channels, NMDA receptors and the transcriptor factor ATF6, which is involved in the unfolding protein response machinary. Considering that altered neuronal calcium homeostasis and the accumulation of poorly folded proteins are common features of many neurodegenerative pathologies, the DREAM modulation could open new avenues for the treatment of neurodegenerative diseases. We recently showed that reduced DREAM expression or blockade of DREAM activity by repaglinide is neuroprotective in Huntington's disease (HD)[1]. However, up to now, only three DREAM binding molecules have been identified. Hence, there is a clear need for the development of chemical tools to modulate and characterize DREAM activity and its interactions. In this communication we will report the identification of novel DREAM modulators by following a multidisciplinary strategy that involves structure-based design, organic chemistry, site-directed mutagenesis and in vitro and in vivo experiments. Our findings open a new avenue in the search of effective treatments of neurodegenerative diseases.
DescriptionResumen del trabajo presentado al 6th European Chemical Biology Symposium ECBS/LS-EuChemS, celebrado en Madrid (España) del 3 al 5 de abril de 2019.
URIhttp://hdl.handle.net/10261/190553
Appears in Collections:(IQM) Comunicaciones congresos
(IIBM) Comunicaciones congresos
(CNB) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.